drugset / Trial / NCT07002112
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase 1
Recruiting
30 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies.
Timeline
- Start
- 2025-05-23
- Primary completion
- 2027-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product | Unknown | — | — |